CD8A and cancer: However, for silvestrol we could show that it potentially strengthens the M2 phenotype by reducing expression of CD206, TREM2 and decreasing the release of pro-inflammatory IL-8 and CCL2, thereby possibly weakening the host’s immune defense against cancer by exhausting CD8+ T cells [10].